Alitretinoin

Interim results from the German REACHED study provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (CHE), with 28.6% of patients assessed as clear or almost clear after eight weeks of treatment, from none at baseline. 1 New post hoc analyses from the phase 3 DELTA TEEN trial show greater reductions in daily HESD itch and pain scores with delgocitinib cream than with cream vehicle in adolescents aged 12-17 with moderate to severe CHE. 2 In an oral presentation, new post hoc analyses from DELTA TEEN show that a higher proportion of adolescents reported no impact on quality of life at Week 16 with delgocitinib cream than with cream vehicle (27.0% vs 0%) 3 BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, has presented new data on delgocitinib cream in Chronic Hand Eczema (CHE) at the 35th European Academy of Dermatology and Venereology (EADV) Congress, held from 30 September to 3 October 2026 in Vienna, Austria. In total, six delgocitinib presentations feature in the company’s programme at the congress, including one oral presentation and five ePosters, spanning adults and adolescents, controlled clinical trials and routine clinical practice, and outcomes reported by physicians and by patients themselves. 1-6 CHE is one of the most common skin diseases of the hands, with an annual prevalence of 4.7% in Western populations, causing itch and pain alongside signs such as fissures, scaling and erythema.⁷,⁸,²⁴ Approximately 70% of adults living with severe CHE report problems with everyday activities.⁹ New data in adolescents A post hoc analysis of the phase 3 DELTA TEEN trial assessed daily patient-reported itch and pain scores using the Hand Eczema Symptom Diary (HESD) in adolescents aged 12-17 with moderate to severe CHE. Mean changes from baseline in HESD itch and pain scores were greater with delgocitinib cream than with cream vehicle at Day 1, for both itch (-1.03±0.20 vs -0.20±0.35, p=0.040) and pain (-1.34±0.22 vs -0.39±0.36, p=0.019), and across the first two weeks of treatment.² In an oral presentation, further DELTA TEEN analyses assessed the impact of CHE on health-related quality of life, using the Children’s Dermatology Life Quality Index (CDLQI), a validated patient-reported questionnaire covering symptoms and feelings, leisure, school, personal relationships and sleep. 3 In post hoc analyses, the proportion of adolescents reporting a CDLQI score of 0 – indicating no impact of their skin disease on quality of life – was significantly higher with delgocitinib cream than with cream vehicle at Week 16 (27.0% vs 0%, p=0.005). 3 The proportion of adolescents reporting a large or very large impact on quality of life (CDLQI 13–30) decreased from 21.6% at baseline to 4.1% at Week 16 with delgocitinib cream, compared with 25.0% to 16.7% with cream vehicle. 3 In the symptoms and feelings domain, improvements from baseline were significantly greater with delgocitinib cream at Week 16 (–1.83±0.14 vs –0.82±0.25, p<0.001), and significantly more adolescents reported a domain score of 0 (48.6% vs 5.0%, p<0.001). 3 "For an adolescent, chronic hand eczema is rarely only a matter of the skin. It shapes how they feel, how they sleep, and what they are willing to do in front of others," said Professor Lawrence F. Eichenfield, Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Diego. "Capturing that alongside clinical severity is what these quality-of-life analyses set out to do, and it is an important part of assessing this condition in younger patients." Real-world evidence in adults Interim results from REACHED, an ongoing prospective, non-interventional study conducted at 79 sites in Germany, provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe CHE. 1 At the interim data cut-off, Week 8 data were available for up to 97 patients, depending on the endpoint.¹ Almost all patients assessed had moderate or severe disease at baseline (63 of 68), with a mean Hand Eczema Severity Index (HECSI) score of 62.4 — within the severe range.¹ After eight weeks of treatment in routine clinical practice, 28.6% of patients were assessed as clear or almost clear (mPGA 0/1), from none at baseline. 1 Mean HECSI scores decreased from 62.4 to 30.8, a change of –28.6 points (95% CI: –37.6, –19.7), and 35.5% of patients achieved at least a 75% improvement in HECSI. 1 Mean Dermatology Life Quality Index (DLQI) scores decreased from 14.5 to 7.9, a change of –6.5 points (95% CI: –7.9, –5.1), and mean itch and pain numerical rating scale scores decreased by –2.1 and –2.7 points respectively. 1 All adverse events reported were non-serious, and all but one were mild or moderate in severity. 1 “Chronic hand eczema is a disease that affect all aspects of everyday life. It can be felt when someone gets dressed, are seen at school, or uses a tool at work, or holds another person’s hand” said Professor Jacob Thyssen, Chief Scientific Officer, LEO Pharma. “The data we are presenting in Vienna describe that experience across the course of the disease – in adults and in adolescents, in clinical trials and in everyday clinical practice, and increasingly in the words of patients themselves. Our commitment is to keep raising the standard of care for a condition that we know affects far more than just the skin.” About the REACHED Study REACHED is an ongoing prospective, observational, non-interventional study describing the real-world effectiveness and safety of delgocitinib cream 20 mg/g in patients with moderate to severe CHE deemed suitable for treatment. Patient enrolment in Germany began on 6 June 2025 and is expected to conclude on 30 June 2026. Effectiveness is evaluated by comparing baseline and follow-up values for the modified Physician Global Assessment (mPGA), Hand Eczema Severity Index (HECSI), Dermatology Life Quality Index (DLQI), and itch and pain numerical rating scales. 1 About the DELTA TEEN Trial DELTA TEEN was a 16-week, phase 3, randomized, double-blind, vehicle-controlled, parallel group, multi-site trial to evaluate the efficacy and safety of twice-daily applications of delgocitinib cream compared with cream vehicle in adolescents 12–17 years of age with moderate to severe CHE. 10 The primary endpoint of DELTA TEEN was the Investigator’s Global Assessment for chronic hand eczema Treatment Success (IGA-CHE TS) at Week 16. Treatment Success was defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline. 10 About Chronic Hand Eczema CHE is one of the most common skin diseases of the hands with a global prevalence rate of approximately 4.7%. 7,18 In a substantial number of patients, HE can develop into a chronic disease. 7 Chronic Hand Eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year. 16,17 CHE is a fluctuating disease characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists. 8 CHE has been shown to cause psychological and functional burdens that impact patient quality of life, 19,20 with approximately 70% of adults who live with severe CHE admitting to problems in performing everyday activities, and suffering disruption in their daily life due to the condition. 9 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE. 21 About Anzupgo® (delgocitinib) Cream Anzupgo cream is a topical non-steroidal pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE. 22 Anzupgo is approved in the European Union, United Kingdom, Switzerland, Canada, Australia, South Korea, and the United Arab Emirates for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. Anzupgo (delgocitinib) cream is FDA approved in the U.S. for moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. In 2014, LEO Pharma obtained the exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where Shionogi & Co., Ltd. owns the rights. About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,300 people worldwide. Together, we reach far beyond the skin. For more information, visit . References Molin S, et al. Real-world effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema: interim analysis after 8 weeks of treatment in the German REACHED study. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. Vienna, Austria. 30 September–3 October 2026. ePoster Presentation. P1613. Molin S, et al. Delgocitinib cream provides rapid improvements in itch and pain symptoms in adolescents with moderate to severe chronic hand eczema: Results from DELTA TEEN. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. Vienna, Austria. 30 September–3 October 2026. ePoster Presentation. P2395. Molin S, et al. Treatment with delgocitinib cream improves health-related quality of life in adolescents with moderate to severe chronic hand eczema: Results from DELTA TEEN; a randomized, double-blind, vehicle-controlled phase 3 trial. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. Vienna, Austria. 30 September–3 October 2026. Oral presentation. AS-1174. Bewley A, et al. Delgocitinib cream reduces patient-reported disease severity in adults with moderate to severe Chronic Hand Eczema: pooled analysis of the Phase 3 DELTA 1 and DELTA 2 trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. Vienna, Austria. 30 September–3 October 2026. ePoster Presentation. P1525. Bauer A, et al. HRQoL and Work Productivity Improvements with Topical Delgocitinib vs Oral Alitretinoin in Chronic Hand Eczema: Phase 3 DELTA FORCE Results. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. Vienna, Austria. 30 September–3 October 2026. ePoster Presentation. P1608. Previously presented at ESCD 2026. Armstrong AW, et al. Sustained Health-Related Quality of Life improvements with Delgocitinib 20 mg/g Cream in Chronic Hand Eczema – Results from the Phase 3 Open-Label Extension DELTA 3 Trial. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. Vienna, Austria. 30 September–3 October 2026. ePoster Presentation. P1576. Previously presented at AAD 2026. Bissonnette R, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24:1–20. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357–378. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158–168. ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adolescents 12–17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN). Identifier: NCT05355818. ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1). Identifier: NCT04871711. ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2). Identifier: NCT04872101. Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461–473. ClinicalTrials.gov. National Library of Medicine (U.S.). Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials (DELTA 3). Identifier: NCT04949841. ClinicalTrials.gov. National Library of Medicine (U.S.). A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema. Identifier: NCT05259722. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267–284. Erratum in: J Cutan Med Surg. 2011;15(6):360. Diepgen TL, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1–22. Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60,000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Presented at the 2024 European Society of Contact Dermatitis Congress; September 4–7, 2024; Dresden, Germany. Poster presentation #3. Grant L, Seiding Larsen L, Burrows K, et al. Development of a conceptual model of chronic hand eczema based on qualitative interviews with patients and expert dermatologists. Adv Ther. 2020;37(2):692–706. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–991. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and severity of hand eczema in the Dutch general population: A cross-sectional, questionnaire study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319–1332. Erratum in: Ther Clin Risk Manag. 2021;17:233. ANZUPGO (delgocitinib) cream. Prescribing Information. FDA. July 2025. Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Br J Dermatol. 2025;192(6):1047–1054. Contacts Jeppe Ilkjær Global Corporate Communications +45 3050 2014 JEILK@leo-pharma.com Christian Bundgaard Global Corporate Communication +45 53 74 88 49 chbun@leo-pharma.com Jes Broe Frederiksen Global Corporate Communication +45 53 60 59 48 jebfe@leo-pharma.com

随着欧洲皮肤病与性病学会（EADV）2026年会的临近，全球皮肤科界的目光即将聚焦于这场学术盛宴。得码学苑特别开设“EADV 2026”专栏，旨在为您系统梳理这场盛会的核心脉络，传递前沿资讯。今日，我们率先启航，深入剖析本届大会的学术内核，聚焦那些将重塑临床实践的关键议题。这不仅是一次对学术热点的前瞻，更是一份为临床医生量身定制的“参会指南”，助您在信息的洪流中精准锚定方向，汲取新知。 01 脱发领域：从非瘢痕性到瘢痕性脱发的诊疗新视角 脱发领域向来是临床研究的热点，本届大会将对此展开深入讨论，涵盖最常见的非瘢痕性脱发与最具挑战的瘢痕性脱发。 雄激素性脱发作为最常见的进行性脱发类型，其病理机制研究持续深化。 本届大会将系统回顾雄激素作用、遗传易感性与毛囊微小化之间的复杂关联，并重点聚焦近一年来最具临床价值的治疗进展。 新型治疗策略、更新后的临床指南以及联合治疗方案的循证证据，正为日常临床实践带来切实可行的优化路径。 而在瘢痕性脱发领域，脱发性毛囊炎（FD）作为最具挑战性的炎症性头皮疾病之一，因其复发性强、临床表现异质且循证治疗手段有限，始终是诊疗难点。 近年来的研究揭示了微生物失调、生物膜形成、固有免疫激活与毛囊免疫豁免状态崩溃之间的复杂相互作用。 值得关注的是，FD与扁平苔藓脱发（LPP）之间的临床表型谱系概念正逐渐被认可， 这一认知挑战了传统上对嗜中性粒细胞性与淋巴细胞性瘢痕性脱发的严格区分，对疾病的早期识别、活动性评估以及治疗策略选择具有深远意义。 基于共识的规范化治疗路径，包括传统药物、联合方案以及新兴靶向疗法，将为长期疾病控制提供更优选择。 02 银屑病治疗：共病管理与治疗前沿的深度对话 银屑病的议题始终是大会的重磅部分，本届大会将从共病、机制到治疗药物进行全面更新。 肥胖与银屑病之间的双向关系已不再停留于流行病学层面。 脂肪组织作为活跃的炎症器官，通过释放脂肪因子持续驱动IL-23/Th17炎症轴，这不仅加重了皮损负担，更显著削弱了生物制剂的应答率与药物生存期。 2026年的多项研究将这一关联转化为可操作的临床洞见：GLP-1受体激动剂在皮肤科的应用基础已被系统梳理， 而“代谢记忆”概念的提出则解释了为何超重与胰岛素抵抗持续影响治疗效果。 早期临床试验已开始探索生物制剂联合减重药物的双重策略，真实世界数据也提示在关注GLP-1类药物可能带来的银屑病关节炎风险信号的同时，将其视为可控的监测变量而非禁忌。 体重，已从共病标签转变为可干预的治疗靶点。 单基因银屑病模型的突破同样令人振奋。传统观念认为银屑病是多基因复杂疾病，但近年研究揭示， 部分患者可能存在单一的遗传缺陷——例如影响RNA编辑并上调I型干扰素免疫应答的基因突变。 这一发现不仅挑战了单一靶向治疗策略的治愈概念，更为精准医学在免疫介导性皮肤病中的应用打开了全新窗口。 理解这些单基因模型及其相关共病，或将重新定义“治愈”的可能。 在局部治疗方面，尽管生物制剂与系统靶向疗法发展迅速，外用药依然是大多数患者的基础管理选择。 本届大会将深入探讨新型非甾体类局部药物、JAK抑制剂局部制剂以及基于纳米技术的递送系统如何提升疗效并减少副作用， 同时强调在特殊部位（如头皮、面部、间擦区）的个体化治疗策略与“激素减量”方案。 03 JAK抑制剂：从作用机制到联合治疗的精准化进程 JAK抑制剂已深刻改变了特应性皮炎、斑秃、银屑病、白癜风及化脓性汗腺炎等多个领域的治疗格局。 然而，其临床效果、起效速度与安全性信号的根本理解，必须回归到JAK-STAT信号通路本身。 本届大会将从分子层面系统阐释四种JAK家族成员的功能差异、不同选择性抑制剂（从第一代泛JAK抑制剂到JAK1优先抑制剂及变构TYK2抑制剂）的药理学特点， 以及这些差异如何转化为临床获益与风险。掌握这一机制框架，将帮助临床医生在日益增多的新分子与新适应症中做出更优选择。 新兴JAK抑制剂的研发管线同样令人期待。从改进选择性谱的新分子，到已有药物的适应症拓展，未来数年将迎来一系列里程碑式进展。 与此同时，面对单药治疗中的应答瓶颈，临床实践中已开始探索JAK抑制剂与其他免疫调节剂或非免疫调节剂的联合方案。 这一组合策略在难治性特应性皮炎中可能突破疗效平台，在斑秃、白癜风等反应较慢的疾病中或可加速应答起效。患者选择、潜在获益与安全性管理是实施联合治疗前的关键考量。 04 儿科皮肤病学：扁平苔藓与血管异常的诊疗挑战 儿童扁平苔藓及苔藓样皮损是一组临床表现多样的界面皮炎，虽不常见，但诊断与治疗极具挑战。 本届大会将结合临床经验与循证指南， 系统梳理儿童扁平苔藓的特征，并重点区分药物性苔藓样疹及苔藓样移植物抗宿主病等关键鉴别诊断。 对于苔藓样小丘疹、条状苔藓等特殊类型，也将通过表格形式呈现与扁平苔藓的鉴别要点，辅助临床医生建立系统诊断框架。 新生儿血管性病变的规范化诊断则需依托国际血管异常研究学会的分类体系。 临床评估应综合发病年龄、部位、生长模式及功能症状（如气道受累、吞咽困难），并警惕PHACE综合征、Klippel-Trénaunay综合征等伴随综合征。 多普勒超声是浅表病变的首选影像学检查，磁共振及CT适用于深部或复杂病例，而数字减影血管造影则主要服务于快速血流型畸形（尤其是动静脉畸形）的术前规划。 对于诊断困难的病例，组织病理学检查仍是金标准。 05 特应性皮炎与手部湿疹：从内型分层到全方位管理 特应性皮炎的异质性正被深入解构。晚发性与早发性患者在临床特征、皮肤免疫谱及系统免疫特征上存在显著差异。 识别晚发性AD这一独特内型，有助于制定更具针对性的治疗策略。 在儿童特应性皮炎的鉴别谱系中，先天性湿疹样综合征不容忽视。 高IgE综合征、Netherton综合征、剥脱性皮肤综合征、先天性免疫缺陷及少汗性外胚层发育不良等罕见遗传病，均可能以湿疹样皮损为首发表现。 近年来对这些疾病发病机制的理解突破，以及靶向治疗的快速发展，使得早期识别与精准干预成为可能。 在更广泛的湿疹范畴中，手部湿疹约影响15%的人群，其慢性化率高，社会经济负担重。 本届大会将聚焦四种病因亚型（刺激性接触性皮炎、过敏性接触性皮炎、蛋白质接触性皮炎/接触性荨麻疹、特应性手部湿疹）与四种临床亚型（角化过度型、急性复发性水疱型、钱币型、指尖湿疹）， 并通过验证性严重程度评分工具指导阶梯式治疗——从基础皮肤护理、局部糖皮质激素及钙调神经磷酸酶抑制剂，到光疗、阿利维A酸、免疫抑制剂及局部泛JAK抑制剂delgocitinib。 此外，淤积性皮炎常被误诊为蜂窝织炎，导致不必要的抗生素使用与住院。其本质是慢性静脉高压引发的炎症反应，易继发过敏性接触性皮炎。 规范化管理需综合压迫疗法、局部抗炎及皮肤屏障修复，警惕溃疡进展并适时进行斑贴试验。 脂溢性皮炎作为一种全球患病率约4.38%的常见炎症性皮肤病，其发病涉及遗传易感、皮脂分泌、屏障破坏、菌群失调及免疫紊乱等多重因素。 治疗以局部抗真菌药、钙调神经磷酸酶抑制剂、糖皮质激素及锌吡硫酮等为主，虽呈慢性复发性，但总体预后良好。 结 语 EADV 2026大会的学术议题设置，清晰地勾勒出皮肤学科的未来方向： 从对疾病机制的深度追问，到共病管理的系统性整合；从新型靶向药物的差异化应用，到基于临床实践的证据探索。 这不仅是知识的盛宴，更是临床思维的革新。 得码学苑将持续为大家深度解析本次大会的精华内容。 在接下来的一段时间里，EADV 2026专栏将陆续为您带来更多壁报精粹、专家访谈和报告解读。 请持续关注得码学苑，与我们一同见证并学习这些即将改变临床实践的前沿进展。 参考来源 [1]https://eadv.org/congress/scientific-programme/ 免责声明 本微信文章中的信息仅供向医疗卫生专业人士提供科学信息，不可直接作为决策内容，得码学苑不对任何主体因使用本文内容而导致的任何损失承担责任。以上内容如涉版权请联系删除。